Literature DB >> 10428426

Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine.

M A Riva1, R Molteni, F Tascedda, A Massironi, G Racagni.   

Abstract

In the present paper we investigated, in the rat brain, the expression of basic fibroblast growth factor (FGF-2) in response to the atypical antipsychotic clozapine. We found that acute or chronic administration of this compound produced a selective increase of FGF-2 mRNA and protein in the striatum. Although acute injection of clozapine did increase FGF-2 expression in parietal cortex and nucleus accumbens we found that, following repeated administration, the induction of the trophic molecule was taking place only at striatal level. The analysis of other antipsychotic drugs did not provide conclusive evidence for the molecular mechanisms involved in clozapine-induced elevation of FGF-2. In fact, chronic administration of classical neuroleptics, haloperidol and chlorpromazine, did not alter the expression of FGF-2. Furthermore the novel drugs quetiapine and olanzapine, despite some similarities in their receptor profiles, were similarly ineffective. Hence these data suggest that, among antipsychotic drugs, the induction of FGF-2 is unique to clozapine. On the basis of the neuroprotective activity of this trophic molecule, our data might be relevant for the potential use of clozapine in tardive dyskinesia and parkinsonism, which develop during long term administration of classical neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428426     DOI: 10.1016/s0028-3908(99)00031-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  11 in total

Review 1.  Fibroblast growth factors in schizophrenia.

Authors:  Afke F Terwisscha van Scheltinga; Steven C Bakker; René S Kahn
Journal:  Schizophr Bull       Date:  2009-05-08       Impact factor: 9.306

Review 2.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

3.  Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents.

Authors:  A M Lindén; J Väisänen; M Lakso; H Nawa; G Wong; E Castrén
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

Review 4.  Possible mechanisms of neurodegeneration in schizophrenia.

Authors:  Iván Pérez-Neri; Jesús Ramírez-Bermúdez; Sergio Montes; Camilo Ríos
Journal:  Neurochem Res       Date:  2006-09-28       Impact factor: 3.996

5.  Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.

Authors:  F Calabrese; A Luoni; G Guidotti; G Racagni; F Fumagalli; M A Riva
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

6.  Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

Authors:  Aoi Syu; Hiroki Ishiguro; Toshiya Inada; Yasue Horiuchi; Syunsuke Tanaka; Maya Ishikawa; Makoto Arai; Masanari Itokawa; Kazuhiro Niizato; Shuji Iritani; Norio Ozaki; Makoto Takahashi; Akiyoshi Kakita; Hitoshi Takahashi; Hiroyuki Nawa; Kazuko Keino-Masu; Eri Arikawa-Hirasawa; Tadao Arinami
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

Review 7.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

Review 8.  Neurogenic actions of atypical antipsychotic drugs and therapeutic implications.

Authors:  Samuel S Newton; Ronald S Duman
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Reduced Insulin-Like Growth Factor Family Member Expression Predicts Neurogenesis Marker Expression in the Subependymal Zone in Schizophrenia and Bipolar Disorder.

Authors:  Christin Weissleder; Maree J Webster; Guy Barry; Cynthia Shannon Weickert
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

Review 10.  Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update.

Authors:  Gerburg Keilhoff; Paolo Fusar-Poli; Axel Becker
Journal:  Neural Plast       Date:  2012-10-24       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.